Shared protein pathology could redefine treatment for multiple neurodegenerative diseases
The paradigm shift argues that shared protein pathology in the nucleus and cytoplasm should drive therapeutic drug development and clinical trials.
The paradigm shift argues that shared protein pathology in the nucleus and cytoplasm should drive therapeutic drug development and clinical trials.